Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Neutral Indegene; target of Rs 552: Motilal Oswal
Motilal Oswal recommended Neutral rating on Indegene with a target price of Rs 552 in its research report dated May 02, 2026.
Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal is bullish on Five Star Business Finance has recommended buy rating on the stock with a target price of Rs 600 in its research report dated April 29, 2026.
Buy Niva Bupa Health Insurance; target of Rs 100: Motilal Oswal
Motilal Oswal recommended is bullish on Niva Bupa Health Insurance recommended buy rating on the stock with a target price of Rs 100 in its research report dated Jun 19, 2026.
Buy Granules India; target of Rs 820: Motilal Oswal
Motilal Oswal is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 820 in its research report dated April 29, 2026.
Buy Mankind Pharma; target of Rs 2640: Motilal Oswal
Motilal Oswal is bullish on Mankind Pharma has recommended buy rating on the stock with a target price of Rs 2640 in its research report dated April 29, 2026.
Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal recommended is bullish on Five Star Business Finance recommended buy rating on the stock with a target price of Rs 600 in its research report dated Jun 22, 2026.
Buy Piramal Pharma; target of Rs 190: Motilal Oswal
Motilal Oswal is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 190 in its research report dated April 29, 2026.
Buy Star Health; target of Rs 640: Motilal Oswal
Motilal Oswal is bullish on Star Health has recommended buy rating on the stock with a target price of Rs 640 in its research report dated April 29, 2026.
PSL offloads 0.6% stake in Sun Pharma Advanced Research, Motilal Oswal buys additional 0.7% stake in Adisoft
Sun Pharma Advanced Research Company shares fell 3.72 percent to Rs 143.04 amid high volumes
Buy Star Health; target of Rs 700: Motilal Oswal
Motilal Oswal is bullish on Star Health recommended buy rating on the stock with a target price of Rs 700 in its research report dated Jun 25, 2026.
LIVE: Nifty fails to hold 24,000; metals outperform | Closing Bell
Markets ended lower, snapping a two-day winning streak, with benchmark indices pressured by weakness in financials and select heavyweight stocks. The Sensex declined over 300 points, while the Nifty failed to hold above the crucial 24,000 mark. Market breadth remained weak, with decliners outnumbering advancers by nearly two-to-one on the BSE, reflecting broad-based selling. Investor caution was also evident as the India VIX climbed around 5%, indicating a pickup in volatility expectations. On the sectoral front, pharma and metal stocks bucked the trend, with the Metal index snapping a three-session losing streak. Banking stocks remained under pressure, dragging the Bank Nifty below the 58,000 mark. Among the Nifty 50 gainers, Dr Reddy's, Max Healthcare and Trent led the advances, while Kotak Mahindra Bank, Mahindra & Mahindra and IndiGo were among the biggest losers of the session.
Buy Rubicon Research; target of Rs 955: Motilal Oswal
Motilal Oswal is bullish on Rubicon Research recommended buy rating on the stock with a target price of Rs 955 in its research report dated April 15, 2026.